Effect of hepatocyte growth factor on invasion of prostate cancer cell lines.
Hepatocyte growth factor (HGF) was suggested to play an important role in the regulation of mitogenesis, motogenesis, angiogenesis, migration and invasion for various types of cells, and acts through a specific membrane receptor encoded by c-met proto-oncogene. However, the mechanism of the effect of HGF on tumor invasion of prostate cancer cells remains unclear. We investigated the effect of HGF on the invasion of PC-3 and DU-145 prostate cancer cells through a reconstituted basement membrane (Matrigel), the haptotactic migration to fibronectin substrate, the expression of protein and mRNA for matrix metalloproteinases (MMP)-1 and -9, membrane-type 1-MMP (MT1-MMP), urokinase-type plasminogen activator (u-PA) and its receptor (uPAR). HGF increased both Matrigel invasion and haptotactic migration of prostate cancer cells. Furthermore, HGF also increased the production of MMP-1 and -9, MT1-MMP, u-PA and uPAR of these cells. These results suggested that HGF increased the invasive potential of prostate cancer cells probably through enhancement of cell motility and the production of MMPs and u-PA.
Fujiuchi
Yasuyoshi
Y
Department of Urology, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama 930-0194, Japan. fujiuchi@ms.toyama-mpu.ac.jp
Nagakawa
Osamu
O
Murakami
Koji
K
Fuse
Hideki
H
Saiki
Ikuo
I
D000970:Antineoplastic Agents / Q000378:metabolism; D002448:Cell Adhesion / Q000187:drug effects; D002465:Cell Movement / Q000187:drug effects; D003094:Collagen; D004338:Drug Combinations; D005337:Fibrin / Q000378:metabolism; D017228:Hepatocyte Growth Factor / Q000494:pharmacology*; D006801:Humans; D007797:Laminin; D008297:Male; D020781:Matrix Metalloproteinase 1 / Q000235:genetics / Q000378:metabolism; D020780:Matrix Metalloproteinase 9 / Q000235:genetics / Q000378:metabolism; D009361:Neoplasm Invasiveness; D011471:Prostatic Neoplasms / Q000201:enzymology / Q000473:pathology*; D011509:Proteoglycans; D000090063:Proto-Oncogene Mas; D012333:RNA, Messenger / Q000378:metabolism; D012334:RNA, Neoplasm / Q000235:genetics; D011956:Receptors, Cell Surface / Q000235:genetics / Q000378:metabolism; D055293:Receptors, Urokinase Plasminogen Activator; D011994:Recombinant Proteins / Q000494:pharmacology; D020133:Reverse Transcriptase Polymerase Chain Reaction; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000235:genetics / Q000378:metabolism; D014407:Tumor Cells, Cultured; D014568:Urokinase-Type Plasminogen Activator / Q000235:genetics / Q000378:metabolism
D000970:Antineoplastic Agents; D004338:Drug Combinations; D007797:Laminin; C000715470:MAS1 protein, human; C524898:PLAUR protein, human; D011509:Proteoglycans; D000090063:Proto-Oncogene Mas; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D011956:Receptors, Cell Surface; D055293:Receptors, Urokinase Plasminogen Activator; D011994:Recombinant Proteins; D019715:Tissue Inhibitor of Metalloproteinase-1; C059485:matrigel; D017228:Hepatocyte Growth Factor; D005337:Fibrin; D003094:Collagen; D014568:Urokinase-Type Plasminogen Activator; D020780:Matrix Metalloproteinase 9; D020781:Matrix Metalloproteinase 1